Cell Therapies – Special Topics – Special Topics: CAR T-Cell Therapy Forecast – Multi-indication
The accelerated approvals of Kymriah (Novartis) for the treatment of children oryoung adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite Pharma, a Gilead company) for relapsed/refractory large B-cell lymphoma herald a new era in cancer immunotherapy. In this report, we present a comprehensive market forecast for the current and emerging chimeric antigen receptor (CAR) T-cell therapies across oncology indications. We also provide key opinion leaders’(KOLs’) insights regarding the current and emerging CAR T-cell treatment landscape.
QUESTIONS ANSWERED
- What is the commercial potential of CAR T-cell therapies by brand, indication, and geography?
- How will the CAR T-cell market evolve over the 2017-2027 forecast period?
- What are the ongoing clinical trials of currently approved CAR T-cell therapies? Which additional indications and settings do we expect Kymriah and Yescarta to secure?
- Which emerging CAR T-cell therapies do we anticipate will gain approval, and will they be commercially successful?
- What are the strengths and weaknesses of each brand, and what are KOLs’ opinions of each therapy?
- What challenges could limit the adoption of autologous CD19-targeted CAR T-cell therapies? What are the competitive threats and pressures thatCAR T-celltherapiesareexpected to face in the oncology landscape?
- What are the opinions of expert oncologists on the future CAR T-cell therapy landscape?
GEOGRAPHIES
United States, EU5, Japan
PRIMARY RESEARCH
14 country-specific interviews with thought-leading hematologist-oncologists and trial investigators.
EPIDEMIOLOGY
Drug-treated patient populations for acute lymphoblastic leukemia, relevant non-Hodgkin’s lymphoma subpopulations, chronic lymphocytic leukemia, and multiple myeloma, by country and line of therapy.
FORECAST
Ten-year, annualized, drug-level sales and patient shares for CAR T-cell therapies through 2027, segmented by indication and patient subpopulation.
PRODUCT DESCRIPTION
The CAR T-Cell Therapy Special Topics Report is a unique product offering a consolidated full market forecast of the CAR T-cell landscape in oncology through 2027. This forecast is supplemented with interviews conducted with KOLs from all seven major pharmaceutical markets under study.
Table of contents
- Cell Therapies - Special Topics - Special Topics: CAR T-Cell Therapy Forecast - Multi-indication
- Special Topics CAR T-Cell Therapies US, EU5, Japan March 2019
Rachel Webster, M.Sc., M.A. (Honors), D.Phil., is principal director and head of the Oncology team at Clarivate. She leads the team in the production of syndicated primary and secondary market research reports and custom analysis of a wide range of oncology indications. Dr. Webster also provides client support for all oncology products and helps biopharmaceutical companies uncover strategic opportunities through data-driven insights from a variety of channels. She has more than ten years of experience in market forecasting and a broad knowledge of oncology indications and markets; she has a particular interest and expertise in immuno-oncology. Previously, Dr. Webster was a research scientist at Immunocore in the target validation group. She has published numerous oncology market assessment articles in Nature Reviews Drug Discovery and, in 2017, developed a new DRG oncology product called Treatment Sequencing. She received her doctorate from the University of Oxford.
Khurram Nawaz, M.Sc., is a senior director on the Oncology team at Clarivate. He manages a team of analysts who conduct extensive primary and secondary market research on the treatment of oncology indications. He also provides sales and client support for syndicated and custom oncology projects, translating domain knowledge into actionable insights. Previously, he was a principal analyst in oncology. He has over a decade of experience in market forecasting and expertise in immuno-oncology, non-small-cell lung cancer, prostate cancer, and a wide range of other solid and hematological malignancies. Prior to joining the company, he contributed to the preclinical development of candidate drugs for schizophrenia and cognitive disorders at GlaxoSmithKline. He obtained his master’s degree in biotechnology from the University of Aix-Marseille and his bachelor’s degree in life sciences from the Pierre and Marie Curie–Paris VI University in France.